Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
March 14th, 2017
We have outlined a method of continuous manual exchange transfusion for the treatment of sickle cell disease in patients. This safe protocol was designed to effectively limit iron overload in patients in need of chronic transfusions and can be used extensively without any special equipment.
The overall goal of this method for continuous manual exchange transfusion is to treat sickle cell diseased patients in need of chronic transfusions while limiting their iron overload without the use of special equipment. This method can help answer key questions in the field of sickle cell anemia, about how to safely and efficiently perform chronic exchange transfusions when electrophoresis is not available. The main advantage of this technique is that it can be performed without specific equipment, but still maintain a similar efficiency to electrophoresis.
Visual demonstration of this method is critical and the continuous phlebotomy steps must be strictly controlled and supervised. Before beginning the exchange transfusion session, have a physician perform a thorough and complete physical examination of the patient, paying specific attention to the body temperature and the hemodynamic parameters and obtain a recent body weight. Install a peripheral venous line to one limb for the phlebotomy and a second venous line to the other limb for the albumin and packed red blood cells infusion.
Then administer one gram of calcium per OS to prevent hypocalcemia due to the presence of a calcium chelating anticoagulant in the transfusion bags. After the results of the exams have been checked, obtain the initial phlebotomy volume using the table as a guide for determining the volume and rate of the acquisition. Program the infusion of the same volume of albumin solution in the syringe pump.
Before beginning the initial phlebotomy, confirm that the appropriate volume of phenotypically-matched packed red blood cells is available at the blood bank for the exchange transfusion. Carefully confirm the compatibility of each delivered blood bag. Just prior to the exchange transfusion, place the patient in the supine position with the feet slightly raised and administer one liter of oxygen via a nasal cannula.
If the patient's hemoglobin level is greater than 8.5 grams per deciliter, begin an initial isovolemic phlebotomy by infusing the 5%albumin solution. After 20 to 50 milliliters of albumin have been infused, unclamp the peripheral intravenous access connected to an empty bleeding bag located below the patient's bed and begin the phlebotomy at the same rate as the albumin infusion. Monitor the patient every five minutes during the initial isovolemic phlebotomy.
If the blood flow is too low, raise the bed to increase the height difference between the arm and the bleeding bag and consequently the blood flow. As the blood is collected, weigh the bleeding bag on a precision scale to adapt the infusion flow in real time to compensate for the volume of blood. At the end of the phlebotomy, use a hemoglobin point of care test to check the hemoglobin levels according to the manufacturer's instructions to confirm that the hemoglobin is around eight grams per deciliter.
For the isovolemic exchange transfusion, begin by transfusing the first 20 milliliters of diluted packed red blood cells before starting the phlebotomy at the same rate of infusion. Monitor the patient every 15 minutes. If the hemoglobin level is higher than 9.5 grams per deciliter, perform an additional phlebotomy compensated by an infusion of the same volume of albumin solution.
At the end of the exchange transfusion, perform the appropriate laboratory tests for determining hemoglobin, hemoglobin S, and calcium levels. Then administer one more gram of calcium per OS, keeping the patient under surveillance for at least one hour after the end of the exchange. As expected, in this representative experiment, the pediatric patients who received electrophoresis only exhibited a very stable ferritinemia.
By comparison, the iron overload generated by a program of chronic red blood cell transfusions was approximately four times greater than that observed under the erythropheresis program. If only patients who received the manual exchange transfusion by the continuous method are considered, a quite stable ferritinemia with an almost equivalent control of iron overload as with erythropheresis is observed. After watching this video, you should have a good understanding of how to perform continuous manual exchange transfusion as a safe and effective alternative for sickle cell patients who need chronic transfusions.
View the full transcript and gain access to thousands of scientific videos
Overview
This article outlines a method for continuous manual exchange transfusion aimed at treating sickle cell disease in patients requiring chronic transfusions. The protocol is designed to limit iron overload without the need for special equipment.
Key Study Components
Area of Science
- Hematology
- Transfusion Medicine
- Sickle Cell Disease
Background
- Sickle cell disease often requires chronic blood transfusions.
- Iron overload is a significant concern in patients receiving frequent transfusions.
- Traditional methods may require specialized equipment.
- This method aims to provide a safe alternative.
Purpose of Study
- To develop a safe protocol for exchange transfusions.
- To limit iron overload in patients.
- To provide a method that does not require special equipment.
Methods Used
- Continuous manual exchange transfusion technique.
- Peripheral venous lines for phlebotomy and infusion.
- Thorough physical examination prior to transfusion.
- Strict control and supervision of phlebotomy steps.
Main Results
- The method can be performed efficiently without specialized equipment.
- Maintains safety and effectiveness similar to electrophoresis.
- Visual demonstration of the method is critical for training.
- Patient monitoring is essential throughout the procedure.
Conclusions
- This method provides a viable alternative for managing sickle cell disease.
- It addresses the challenge of iron overload in chronic transfusions.
- Further research may enhance its application in clinical settings.
Frequently Asked Questions
Executive Industry Relevance
Chronic transfusion programs for sickle cell disease face the challenge of iron overload, limiting long-term therapeutic utility. This method provides a low-resource alternative to erythropheresis, enabling iron overload mitigation without specialized equipment. It supports predictive confidence in transfusion safety and broadens accessibility across diverse clinical settings.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of transfusion efficacy in hemoglobin S reduction and stroke prevention models.
- Operational Value: Supports preclinical evaluation of chronic transfusion strategies in resource-limited environments.
Screening & Assay Development
- Scientific Value: Facilitates standardized blood exchange for consistent pharmacokinetic and pharmacodynamic readouts.
- Operational Value: Ensures reproducible hematologic parameters across experimental cohorts.
Translational & Preclinical Research
- Scientific Value: Models chronic transfusion effects while monitoring iron accumulation as a translational biomarker.
- Operational Value: Enables longitudinal studies in sickle cell disease models with controlled iron exposure.
Pipeline & Workflow Integration
The method integrates into discovery workflows requiring chronic transfusion support, particularly where erythropheresis is unavailable, enabling continuity from target validation to preclinical efficacy testing.
- Discovery Biology: Supports hypothesis testing on transfusion-mediated pathophysiology modification.
- Screening: Provides assay-ready biological systems with stable hemoglobin S levels.
- Analytics: Enables quantitative measurement of hemoglobin, hemoglobin S, and ferritin levels over time.
- Translational Research: Connects discovery findings to preclinical iron overload mitigation strategies.
- Enterprise Reuse: Represents a scalable, equipment-free capability for transfusion-dependent disease models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in transfusion safety and reduction of iron overload confounding.
- Operational Value: Standardization, reproducibility, and minimal instrumentation requirements.
- Strategic Value: Improved go/no-go decisions in transfusion-dependent disease models.
- Portfolio Impact: Risk-adjusted prioritization of therapies requiring chronic transfusion support.
Implementation Considerations
- Requires clinical expertise in transfusion medicine and hematology.
- Dependent on peripheral venous access and precision weighing equipment.
- Necessitates standardized training for phlebotomy and infusion rate control.
- Adaptation considerations include patient-specific hemoglobin targets and blood product compatibility.
- Practical limitations include manual effort intensity and need for vigilant monitoring.
Biopharma FAQs
Chapters in this video
0:05
Title
0:54
Patient and Blood Product Preparation
2:20
Optional Initial Isovolemic Phlebotomy
3:25
Isovolemic Exchange Transfusion and Final Laboratory Test
4:13
Results: Representative Iron Overloads during Manual Exchange Transfusion or Erythrapheresis Programs
4:54
Conclusion
